Market Research Logo

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Israel

1 Table of Contents
1.1 List of Tables
1.2 List of Figures
2 Introduction
2.1 GlobalData Report Guidance
3 Overview of the Pharmaceutical and Medical Device Markets
3.1 Pharmaceutical Market
3.1.1 Market Overview
3.1.2 Pharmaceutical Exports and Imports
3.1.3 Supply Channels
3.1.4 Market Segments
3.1.5 Overview of Top Five Disease Areas
3.1.6 Major Players
3.2 Medical Device Market
3.2.1 Market Overview
3.2.2 Overview of Top Five Segments
3.2.3 Major Players
3.3 Market Drivers and Barriers
3.3.1 Drivers
3.3.2 Barriers
4 Market Access
4.1 Reimbursement and Payer Landscape
4.1.1 Overview of Healthcare System
4.1.2 Reimbursement Process
4.1.3 Overview of Insurance Providers
4.1.4 Patient Share in Healthcare Spending
4.1.5 Price Trend in Healthcare Services
4.1.6 Pricing Policies
4.2 Regulatory Landscape
4.2.1 Overview of Regulatory Agencies
4.2.2 Market Authorization Procedure for Pharmaceutical Products
4.2.3 Market Authorization Procedure for Medical Devices
4.2.4 Licensing Process for Pharmaceutical and Medical Device Manufacturing
4.2.5 Licensing Process for Pharmaceutical Exports and Imports
4.2.6 Intellectual Property Rights
4.2.7 Clinical Trial Regulations
4.2.8 Pharmaceutical Advertising Regulations
4.2.9 Pharmacy Regulations
4.2.10 Labeling and Packaging Regulations
5 Country Analysis
5.1 Political Environment
5.1.1 Political Structure
5.1.2 Analysis of Current Political Environment
5.1.3 Healthcare Policy Initiatives
5.2 Economic Landscape
5.3 Economic Indicators
5.3.1 Gross Domestic Product
5.3.2 Gross National Income
5.3.3 Inflation
5.3.4 Currency Exchange Rate
5.3.5 Foreign Direct Investment
5.3.6 Foreign Exchange Reserves
5.3.7 Trade Balance
5.3.8 General Government Structural Balance
5.3.9 General Government Net Debt
5.3.10 Major Industries
5.4 Demographics
5.4.1 Population
5.4.2 Education and Literacy
5.4.3 Employment
5.4.4 Disease Burden
5.5 Healthcare Infrastructure
5.5.1 Healthcare Facilities
5.5.2 Healthcare Parameters
5.5.3 Environmental Health
5.5.4 Healthcare Personnel
5.6 Healthcare Expenditure
5.6.1 Overview
5.6.2 Public and Private Sector Share
5.6.3 Major Components of Healthcare Spending
5.6.4 Healthcare Expenditure by Financing Agent
5.6.5 Spending in Science and Technology R&D
5.7 Trade Associations
5.7.1 Pharmaceutical Association of Israel
5.7.2 Pharma Israel
5.8 Trade Fairs
6 Opportunities and Challenges
6.1 Opportunities
6.2 Challenges
7 Appendix
7.1 Abbreviations
7.2 Bibliography
7.3 Research Methodology
7.3.1 Coverage
7.3.2 Secondary Research
7.3.3 Forecasts
7.3.4 Expert Panel
7.4 Disclaimer
1.1 List of Tables
Table 1: Peripheral Vascular Stents - Pipeline Products by Stage of Development
Table 2: Peripheral Vascular Stents - Pipeline Products by Segment
Table 3: Peripheral Vascular Stents - Pipeline Products by Territory
Table 4: Peripheral Vascular Stents - Pipeline Products by Regulatory Path
Table 5: Peripheral Vascular Stents - Pipeline Products by Estimated Approval Date
Table 6: Peripheral Vascular Stents - Ongoing Clinical Trials
Table 7: Peripheral Vascular Stents Companies - Pipeline Products by Stage of Development
Table 8: Peripheral Vascular Stents - Pipeline Products by Stage of Development
Table 9: 3D Biotek LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 10: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Status
Table 11: Bioresorbable Drug Eluting Peripheral Polymer Stent - Product Description
Table 12: 480 Biomedical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 13: Stanza Bioresorbable Pediatric Scaffold - Product Status
Table 14: Stanza Bioresorbable Pediatric Scaffold - Product Description
Table 15: Stanza Bioresorbable Self-Expanding Scaffold - Product Status
Table 16: Stanza Bioresorbable Self-Expanding Scaffold - Product Description
Table 17: 480 Biomedical Inc - Ongoing Clinical Trials Overview
Table 18: Stanza Bioresorbable Self-Expanding Scaffold - An Evaluation of the 480 Biomedical STANZA Drug-Eluting Resorbable Scaffold (DRS) System in the Treatment of de Novo SFA Lesions
Table 19: Abbott Vascular Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 20: ESPRIT Bioresorbable Vascular Scaffold - Product Status
Table 21: ESPRIT Bioresorbable Vascular Scaffold - Product Description
Table 22: Biotronik SE & Co KG Pipeline Products & Ongoing Clinical Trials Overview
Table 23: Astron Pulsar Self Expanding Peripheral Stent - Product Status
Table 24: Astron Pulsar Self Expanding Peripheral Stent - Product Description
Table 25: Pulsar-18 Self Expanding Stent - Product Status
Table 26: Pulsar-18 Self Expanding Stent - Product Description
Table 27: Biotronik SE & Co KG - Ongoing Clinical Trials Overview
Table 28: Astron Pulsar Self Expanding Peripheral Stent - The Treatment of Iliac and Femoral Atherosclerotic Lesions Using the Self-expanding Astron and Pulsar-18 Stents (BIOFLEX-I Europe)
Table 29: Pulsar-18 Self Expanding Stent - BIOFLEX PEACE All-comers Trial
Table 30: Pulsar-18 Self Expanding Stent - Physician-Initiated Trial Investigating the Efficacy of Endovascular Treatment of Femoropopliteal Arterial Stenotic Disease with the Biotronik Passeo-18 Lux Drug Releasing Balloon and the Biotronik Pulsar-18 Stent (Comparing with 4EVER Trial Results) (BIOLUX 4EVER)
Table 31: Boston Scientific Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 32: Cobalt-Chromium Iliac Balloon Expandable Stent - Product Status
Table 33: Cobalt-Chromium Iliac Balloon Expandable Stent - Product Description
Table 34: Eluvia Drug-Eluting Vascular Stent System - Product Status
Table 35: Eluvia Drug-Eluting Vascular Stent System - Product Description
Table 36: Gallbladder Drainage System - Product Status
Table 37: Gallbladder Drainage System - Product Description
Table 38: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Status
Table 39: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Product Description
Table 40: Boston Scientific Corp - Ongoing Clinical Trials Overview
Table 41: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Bare Metal Self-expanding Nitinol Stents in the Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Table 42: Eluvia Drug-Eluting Vascular Stent System - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Table 43: Eluvia Drug-Eluting Vascular Stent System - Stenting of the Superficial Femoral and/or Proximal Popliteal Artery Project with Boston Scientific's Innova Drug Eluting Stent
Table 44: Wallstent RP Endoprosthesis - Venous Outflow Obstruction - Sinai Vein Stent Registry
Table 45: C. R. Bard Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 46: VENOVO Venous Stent - Product Status
Table 47: VENOVO Venous Stent - Product Description
Table 48: Cardiatis SA Pipeline Products & Ongoing Clinical Trials Overview
Table 49: Cardiatis FluidSmart 3D Stent - Product Status
Table 50: Cardiatis FluidSmart 3D Stent - Product Description
Table 51: Cook Medical Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 52: Evolution Biliary Stent System-Partially Covered - Product Status
Table 53: Evolution Biliary Stent System-Partially Covered - Product Description
Table 54: Evolution Esophageal Stent System-Fully Covered - Product Status
Table 55: Evolution Esophageal Stent System-Fully Covered - Product Description
Table 56: Zenith Connection Endovascular Covered Stent - Product Status
Table 57: Zenith Connection Endovascular Covered Stent - Product Description
Table 58: Zenith Helical Branch Iliac Endovascular Graft - Product Status
Table 59: Zenith Helical Branch Iliac Endovascular Graft - Product Description
Table 60: ZILVER PTX Drug Eluting Peripheral Stent - Product Status
Table 61: ZILVER PTX Drug Eluting Peripheral Stent - Product Description
Table 62: Zilver Vena Venous Self-Expanding Stent - Product Status
Table 63: Zilver Vena Venous Self-Expanding Stent - Product Description
Table 64: Cook Medical Inc - Ongoing Clinical Trials Overview
Table 65: ZILVER PTX Drug Eluting Peripheral Stent - A Randomized Trial Comparing the ELUVIA Drug-eluting Stent Versus Zilver PTX Stent for Treatment of Superficial Femoral and/or Proximal Popliteal Arteries
Table 66: ZILVER PTX Drug Eluting Peripheral Stent - Bare Metal Stent Versus Paclitaxel Eluting Stent in the Setting of Primary Stenting of Intermediate Length Femoropopliteal Lesions
Table 67: ZILVER PTX Drug Eluting Peripheral Stent - Comparison of the Primary Long Versus Short Coverage with Drug-Eluting Stents for Long Femoropopliteal Artery Disease (PARADE II): Investigator-initiated Clinical Study
Table 68: ZILVER PTX Drug Eluting Peripheral Stent - Drug Eluting Stent for the Management of Peripheral Arterial Disease of the SFA (DESPERADO-SFA Study)
Table 69: ZILVER PTX Drug Eluting Peripheral Stent - Evaluation of the Zilver PTX Drug-eluting Peripheral Stent for Treatment of Lesions of the Above-the-knee Femoropopliteal Artery
Table 70: ZILVER PTX Drug Eluting Peripheral Stent - Paclitaxel-coated Peripheral Stents Used in the Treatment of Femoropopliteal Stenoses
Table 71: ZILVER PTX Drug Eluting Peripheral Stent - The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery for the Treatment The Cook Zilver PTX Drug-eluting Stent Versus Bypass Surgery of Femoropopliteal TASC C&D Lesions (ZILVERPASS)
Table 72: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Drug-eluting Peripheral Stent Post-approval Study
Table 73: ZILVER PTX Drug Eluting Peripheral Stent - Zilver PTX Post-market Surveillance Study of Paclitaxel-eluting Stents for Treating Femoropopliteal Artery Disease in Japan
Table 74: Zilver Vena Venous Self-Expanding Stent - Evaluation of the Zilver Vena Venous Stent in the Treatment of Symptomatic Iliofemoral Venous Outflow Obstruction
Table 75: Evolution Esophageal Stent System-Fully Covered - Clinical Investigation to Evaluate Removal of the Evolution Esophageal Stent - Fully Covered
Table 76: Cordis Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 77: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Status
Table 78: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Product Description
Table 79: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Status
Table 80: FlexStent Self Expanding Below-The-Knee Venous Stent System - Product Description
Table 81: FlexStent Self Expanding Venous Stent System - Product Status
Table 82: FlexStent Self Expanding Venous Stent System - Product Description
Table 83: Tibial SE FlexStent - Product Status
Table 84: Tibial SE FlexStent - Product Description
Table 85: Cordis Corp - Ongoing Clinical Trials Overview
Table 86: FlexStent Femoropopliteal Self Expanding Stent System - SFA - Evaluation of Safety and Efficacy of the FlexStent Femoropopliteal Self-expanding Stent System Study
Table 87: Corinnova Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 88: Hybrid Dynamic Stent - Product Status
Table 89: Hybrid Dynamic Stent - Product Description
Table 90: Cytograft Tissue Engineering Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 91: LifeJacket Stent Graft - Peripheral - Product Status
Table 92: LifeJacket Stent Graft - Peripheral - Product Description
Table 93: Efferent Labs Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 94: RTI-LICD Plexisense - Product Status
Table 95: RTI-LICD Plexisense - Product Description
Table 96: Electroformed Stents Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 97: Helical Stent - Product Status
Table 98: Helical Stent - Product Description
Table 99: Patch Stent - Product Status
Table 100: Patch Stent - Product Description
Table 101: Pleated Stent - Product Status
Table 102: Pleated Stent - Product Description
Table 103: Elixir Medical Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 104: PRAVA Bioresorbable Scaffold - Product Status
Table 105: PRAVA Bioresorbable Scaffold - Product Description
Table 106: Elixir Medical Corp - Ongoing Clinical Trials Overview
Table 107: PRAVA Bioresorbable Scaffold - Drug Eluting Scaffold with an Absorbable Platform for Primary Lower Extremity Arterial Revascularization (DESappear Study)
Table 108: Hexacath Pipeline Products & Ongoing Clinical Trials Overview
Table 109: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Status
Table 110: HELIOS LD Peripheral Balloon Expandable Bio Active Stent - Product Description
Table 111: InspireMD Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 112: PVGuard Peripheral - Product Status
Table 113: PVGuard Peripheral - Product Description
Table 114: Intact Vascular, LLC Pipeline Products & Ongoing Clinical Trials Overview
Table 115: Tack Endovascular System - BTK - Product Status
Table 116: Tack Endovascular System - BTK - Product Description
Table 117: Intact Vascular, LLC - Ongoing Clinical Trials Overview
Table 118: Tack Endovascular System - BTK - Prospective, Multicenter Tack Optimized Balloon Angioplasty below the Knee (TOBA - BTK) Study for Infrapopliteal Arteries Using the Tack-it Endovascular System
Table 119: Tack Endovascular System - BTK - Tack Optimized Balloon Angioplasty Study for the below the Knee Arteries Using the Tack Endovascular System
Table 120: Lifetech Scientific (Shenzhen) Co., Ltd. Pipeline Products & Ongoing Clinical Trials Overview
Table 121: Peripheral Bare Stent - Product Status
Table 122: Peripheral Bare Stent - Product Description
Table 123: Peripheral Cover Stent - Product Status
Table 124: Peripheral Cover Stent - Product Description
Table 125: LimFlow GmbH Pipeline Products & Ongoing Clinical Trials Overview
Table 126: LimFlow Stent Graft System - Product Status
Table 127: LimFlow Stent Graft System - Product Description
Table 128: Medinol Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 129: ChampioNIR - Product Status
Table 130: ChampioNIR - Product Description
Table 131: Medtronic plc Pipeline Products & Ongoing Clinical Trials Overview
Table 132: Maris - Product Status
Table 133: Maris - Product Description
Table 134: MicroVention, Inc. Pipeline Products & Ongoing Clinical Trials Overview
Table 135: CASPER Carotid Stent - Product Status
Table 136: CASPER Carotid Stent - Product Description
Table 137: Natec Medical Ltd Pipeline Products & Ongoing Clinical Trials Overview
Table 138: Marina - Product Status
Table 139: Marina - Product Description
Table 140: Nexeon MedSystems Inc Pipeline Products & Ongoing Clinical Trials Overview
Table 141: CITATION Peripheral Stent System - Product Status
Table 142: CITATION Peripheral Stent System - Product Description
Table 143: Nipro Corp Pipeline Products & Ongoing Clinical Trials Overview
Table 144: Peripheral Stent - Product Status
Table 145: Peripheral Stent - Product Description
1.2 List of Figures
Figure 1: Pharmaceutical Market, Israel, Revenue ($bn), 2008-2015
Figure 2: Pharmaceutical Market, Israel, Revenue ($bn), 2016-2020
Figure 3: Pharmaceutical Market, Israel, Exports and Imports ($bn), 2008-2015
Figure 4: Pharmaceutical Market, Israel, Over-the-Counter Market, Revenue ($m), 2008-2015
Figure 5: Medical Device Market, Israel, Revenue ($bn), 2008-2015
Figure 6: Medical Device Market, Israel, Revenue ($bn), 2016-2020
.Figure 7: Medical Device Market, Israel, Revenue by Segment ($m), 2015
Figure 8: Medical Device Market, Israel, Nephrology and Urology Devices ($m), 2008-2015
Figure 9: Nephrology and Urology Devices, Israel, Market Share of Leading Companies (%), 2012
Figure 10: Medical Device Market, Israel, In Vitro Diagnostics ($m), 2008-2015
Figure 11 In Vitro Diagnostics, Israel, Market Share of Leading Companies (%), 2012
Figure 12: Medical Device Market, Israel, Cardiovascular Devices ($m), 2008-2015
Figure 13: Cardiovascular Devices, Israel, Market Share (%) of Leading Companies, 2015
Figure 14: Medical Device Market, Israel, Ophthalmic Devices ($m), 2008-2015
Figure 15: Ophthalmic Devices, Israel, Market Share (%) of Leading Companies, 2012
Figure 16: Medical Device Market, Israel, Drug Delivery Devices Market ($m), 2008-2015
Figure 17: Drug Delivery Devices Market, Israel, Market Share (%) of Leading Companies, 2008-2012
Figure 18: Medical Device Market, Israel, Revenue of Leading Companies ($m), 2015
Figure 19: Healthcare Market, Israel, Drivers and Barriers, 2016
Figure 20: Healthcare System, Israel, Overview of Healthcare System, 2015
Figure 21: Healthcare Spending, Israel, Out-of-Pocket Expenditure (%), 2008-2014
Figure 22: Market Access, Israel, Change in Prices of Medicines (%), 2008-2015
Figure 23: Market Access, Israel, Overview of Regulatory Bodies, 2016
Figure 24: Economic Indicators, Israel, Gross Domestic Product per Capita ($), 2008-2015
Figure 25: Economic Indicators, Israel, Gross Domestic Product per Capita ($), 2016-2020
Figure 26: Economic Indicators, Israel, Gross Domestic Product Annual Growth (%), 2008-2015
Figure 27: Economic Indicators, Israel, Gross Domestic Product Annual Growth (%), 2016-2020
Figure 28: Economic Indicators, Israel, Gross National Income per Capita ($), 2008-2015
Figure 29: Economic Indicators, Israel, Average Consumer Price Index, 2008-2015
Figure 30: Economic Indicators, Israel, Average Consumer Price Annual Change (%), 2008-2015
Figure 31: Economic Indicators, Israel, Currency Exchange Rate (ILS/$), 2008-2015
Figure 32: Economic Indicators, Israel, Foreign Direct Investment ($bn), 2008-2015
Figure 33: Economic Indicators, Israel, Foreign Exchange Reserves ($bn), 2008-2015
Figure 34: Economic Indicators, Israel, Imports of Goods and Services ($bn), 2008-2015
Figure 35: Economic Indicators, Israel, Exports of Goods and Services ($bn), 2008-2015
Figure 36: Economic Indicators, Israel, Government Structural Balance ($bn), 2008-2015
Figure 37: Economic Indicators, Israel, General Government Net Debt as Percentage of GDP (%), 2008-2015
Figure 38: Economic Indicators, Israel, Major Industries by Revenue (%), 2014
Figure 39: Demographics, Israel, Population (million), 2008-2015
Figure 40: Demographics, Israel, Population (million), 2016-2020
Figure 41: Demographics, Israel, Population, Urban and Rural Population Share (%), 2008-2015
Figure 42: Demographics, Israel, Population, Urban and Rural Population Share (%), 2014-2020
Figure 43: Demographics, Israel, Population Distribution by Age Group (%), 2008-2015
Figure 44: Demographics, Israel, Population Distribution by Age Group (%), 2016-2020
Figure 45: Demographics, Israel, Births (per 1,000 population), 2008-2014
Figure 46: Demographics, Israel, Mortality (per 1,000 population), 2008-2014
Figure 47: Demographics, Israel, Major Causes of Mortality, 2013
Figure 48: Demographics, Israel, Infant Mortality (per 1,000 live births), 2008-2015
Figure 49: Demographics, Israel, Immunization Rate (%), 2008-2014
Figure 50: Demographics, Israel, Major Causes of Male Mortality (per 100,000 population), 2013
Figure 51: Demographics, Israel, Major Causes of Female Mortality (per 100,000 population), 2013
Figure 52: Demographics, Israel, Gender Ratio (M/F), 2008-2015
Figure 53: Demographics, Israel, Life Expectancy at Birth (years), 2008-2015
Figure 54: Demographics, Israel, Life Expectancy at Birth (years), 2016-2020
Figure 55: Demographics, Israel, Enrollment by Level of Education (‘000), 2009-2014
Figure 56: Demographics, Israel, Unemployment Rate (%), 2008-2015
Figure 57: Demographics, Israel, Distribution of Male Employment by Occupation (%), 2014
Figure 58: Demographics, Israel, Distribution of Female Employment by Occupation (%), 2014
Figure 59: Demographics, Israel, Number of Reported Cases per Disease (per 1,000 population), 2009
Figure 60: Demographics, Israel, Major Diseases, Disability-Adjusted Life Years (‘000), 2012
Figure 61: Healthcare Infrastructure, Israel, Number of Hospital Establishments, 2008-2014
Figure 62: Healthcare Infrastructure, Israel, Public and Private Hospitals, 2008-2014
Figure 63: Healthcare Infrastructure, Israel, Type of Hospital Care, 2008-2014
Figure 64: Healthcare Infrastructure, Israel, Diagnostic Equipment (per million population), 2008-2015
Figure 65: Healthcare Infrastructure, Israel, Hospital Beds (per 1,000 population), 2008-2015
Figure 66: Healthcare Infrastructure, Israel, Doctors (per 1,000 population), 2008-2014
Figure 67: Healthcare Infrastructure, Israel, PM2.5 (µg/m3), 2008-2014
Figure 68: Healthcare Infrastructure, Israel, Carbon Dioxide Emissions (million metric tons), 2008-2014
Figure 69: Healthcare Infrastructure, Israel, Nurses (per 1,000 population), 2008-2014
Figure 70: Healthcare Infrastructure, Israel, Pharmacists (per 1,000 population), 2008-2014
Figure 71: Healthcare Infrastructure, Israel, Dentists (per 1,000 population), 2008-2014
Figure 72: Healthcare Expenditure, Israel, Healthcare Expenditure as a Percentage of GDP (%), 2008-2015
Figure 73: Healthcare Expenditure, Israel, Public-Private Share (%), 2008-2014
Figure 74: Healthcare Expenditure, Israel, Primary Healthcare Expenditure by Sector (%), 2012
Figure 75: Healthcare Expenditure, Israel, Financing Agents (%), 2014
Figure 76: Healthcare Expenditure, Israel, GDP Expenditure on R&D in Sciences ($bn), 2008-2014
Figure 77: Healthcare Market, Israel, Opportunities and Challenges, 2016

CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Israel

Summary

GlobalData, the industry analysis specialist, has released its latest report, “CountryFocus: Healthcare, Regulatory and Reimbursement Landscape - Israel”. The report is an essential source of information and analysis on the healthcare, regulatory and reimbursement landscape in Israel. It identifies the key trends in the healthcare market and provides insights into the demographic, regulatory, reimbursement landscape and healthcare infrastructure of Israel. Most importantly, the report provides valuable insights into the trends and segmentation of the pharmaceutical and medical device markets. It is built using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData’s team of industry experts.

In 2015, Israel population was approximately at 8.4 million. The government of Israel has been making continuous efforts to strengthen the economy to ensure long-term growth, and the pharmaceutical market is seen as a key industry for the country’s future growth. To support this industry, the government has improved regulatory guidelines and initiatives to develop the domestic pharmaceutical market. The Pharmaceutical market was estimated to be worth $1.75 billion in 2015 and expected to reach $2.12 billion by 2020. The market grew nominally at a Compound Annual Growth Rate (CAGR) of 3.9% over the 2008-2020 period. The medical device market was valued at $0.97 billion in 2008 and is expected to reach approximately $1.55 billion by 2020, at a projected CAGR of 4%.

These positive trends can primarily be attributed to -

  • An increasing elderly population in Israel, leading to increases in disease incidence and prevalence as well as higher need for long-term care and medical devices
  • Increasing awareness in the medical community and the general population regarding early disease detection and diagnosis, leading to higher rates of adoption of treatments and healthcare
Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape in Israel, and includes -
  • An overview of the pharmaceutical and medical device markets, comprising market size, segmentation, and key drivers and barriers
  • Profiles and SWOT analyses of the major players in the pharmaceutical market (Teva, Taro, Dexcel and Rekah)
  • An insightful review of the reimbursement and regulatory landscape, of which analysis includes details of the healthcare reimbursement process, the regulatory agencies and the approval processes for new drugs and medical devices
  • Detailed analysis of the political and economic environment, covering economic indicators, demographics, healthcare infrastructure and healthcare expenditure
  • An overview of the opportunities for and challenges to growth in the Israel healthcare market
Reasons to buy
  • This report will enhance your decision-making capability by allowing you to
  • Develop business strategies by understanding the trends shaping and driving Israel healthcare market
  • Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical market segments, and companies likely to impact the healthcare market in the future
  • Formulate effective sales and marketing strategies by understanding the competitive landscape and analyzing the performance of various competitors
  • Organize your sales and marketing efforts by identifying the market categories and segments that present the most opportunities for consolidation, investment, and strategic partnership
  • Identify, understand, and capitalize on the opportunities and challenges in Israel healthcare market


Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report

;